# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-24-094619
Filing Date
2024-11-05
Accepted
2024-11-05 17:00:36
Documents
6
Period of Report
2024-11-27

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PROXY STATEMENT | ea0219744-01.htm | DEF 14A | 1237575
2 | GRAPHIC | tactinium_logo.jpg | GRAPHIC | 134725
3 | GRAPHIC | tbarchart_001.jpg | GRAPHIC | 406676
4 | GRAPHIC | tbarchart_002.jpg | GRAPHIC | 386387
5 | GRAPHIC | tproxy_001.jpg | GRAPHIC | 1057019
6 | GRAPHIC | tproxy_002.jpg | GRAPHIC | 1205740
| Complete submission text file | 0001213900-24-094619.txt |  | 5634231

Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 241428397
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)